July 2016 – In this Issue

Education | Society & Forward Fund | Science & Research
Membership | Publications

A Message from the President

Dear Colleagues,

The Society for Immunotherapy of Cancer (SITC) will soon begin the process of electing its new leaders who will be installed at the 2016 Annual Meeting this fall. As we look forward to the November meeting, I am very excited for our society to come together to celebrate our accomplishments over the past year. I am so proud of SITC and humbled to be a part of such an incredible society.

Stakeholders Collaborate at SITC 2016
As you know, SITC’s Annual Meeting is the world’s leading cancer immunotherapy gathering where cutting edge data is presented by luminaries in the field. The meeting provides a venue where stakeholders can collaborate and steer the future of immunotherapy as a cancer treatment modality. Consider submitting an abstract to SITC 2016. The deadline is August 8 – so you have a few more weeks to get involved and encourage colleagues to do the same.

SITC Attends Cancer Moonshot Summit
SITC is also increasing its efforts in the public policy arena by advocating for those in the cancer immunotherapy field. The recent National Cancer Moonshot Summit, led by Vice President Joe Biden, took immunotherapy one step closer to where it needs to be – in the mainstream of cancer treatment. Tara Withington, SITC Executive Director, along with many SITC members, participated on behalf of the society in Washington, D.C. Beyond the onsite summit, SITC took to Twitter and continued to lead the way through a virtual summit of our own. SITC will continue discussing ways in which the Cancer Moonshot Initiative could assist in improving patient outcomes. Check out #SITCSummit to join the conversation. Read more.

SITC Film Advances Hope
In response to recent FDA drug approvals in non-small lung cancer immunotherapy, SITC is pleased to announce a new video titled Non-Small Cell Lung Cancer Immunotherapy: Advancing Hope™. This is the second video in the series and educates healthcare providers on immunotherapy, FDA approved immunotherapies, the importance of clinical trials, and potential side effects from treatment. Our goal is to initiate a shared decision-making process in which the physician, nurse and patient can have an informed discussion with one another to select the best treatment option for the individual. For the advanced level of learning needed for healthcare professionals, SITC is now offering CME/CNE certified online activity for physicians and nurses to complete through CME University. Help advance hope today by sharing this video on social media and with your family and friends.

I want to thank those who have been involved in cancer immunotherapy during this time of growth. Your continued commitment to the field moves us closer to the word cure.

Best regards,

Howard L. Kaufman, MD, FACS
SITC President

Education

Non-Small Cell Lung Cancer Immunotherapy: Advancing Hope^TM

SITC has partnered with leading lung cancer experts and patient advocacy groups to create the short film Non-Small Cell Lung Cancer Immunotherapy: Advancing Hope^TM. The film follows a non-small cell lung cancer (NSCLC) patient who is introduced to immunotherapy and is looking to determine if it is the right treatment option for him.

Designed to comprehensively educate patients, physicians and registered nurses in immunotherapy as a treatment option for NSCLC, it will facilitate informed discussions between patient and healthcare teams to create a shared decision-making process.

In addition to the film, SITC is pleased to offer a companion online CME- and CNE-certified activity comprised of detailed written case studies. It is designed to provide physicians and registered nurses with a more in-depth overview of what they will need to know when considering and utilizing immunotherapy with NSCLC patients in the clinical setting. Learn more.

Cancer Immunotherapy 101

Do you know a clinical provider who helps cancer patients and wants
to learn more about cancer immunotherapy?

New York, New York – Thursday, August 18

Seattle, Washington – Friday, August 19

Boston, Massachusetts – Thursday, September 8

Baltimore, Maryland – Friday, September 30

Portland, Oregon – Thursday, October 13

Charlottesville, Virginia – Thursday, October 14

SITC's 31^st Annual Meeting & Associated Programs
The world's leading immunotherapy meeting

Gaylord National Hotel & Convention Center
National Harbor, Maryland | November 9 – 13, 2016

Plan to Attend
Register and get your hotel now. Space is filling up quickly.

Present Your Work
Submissions are due on August 8, 2016 at 5:00 pm EST for:

• Abstracts – In addition to eligibility for oral speaking spots and poster presentations
  at the meeting, 31 Young Investigators will be selected to recieve Travel Awards.
  Learn more.

• Applications for Industry Program – Industry personnel are invited to submit for
  a speaking spot in the New Cancer Immunotherapy Agents in Development program.
  Learn more.

Reserve Your Exhibit Booth/Ancillary Event Venue
Space is filling up fast at SITC 2016! Reserve your exhibit booth today or host an event at SITC.
Learn more.

Support SITC 2016
SITC offers a wide array of support opportunities for corporate partners, allowing them to gain exposure and educate meeting attendees on their products and services. Learn more.

Society & Forward Fund

Apply for the SITC-Bristol-Myers Squibb Cancer Immunotherapy
Translational Fellowship

Submission Period: July 18 — August 29, 2016
This two-year $200,000 award aims to provide dedicated funding for an individual who has an MD or combined MD/PhD and a vested interest in furthering the research and translation of cancer immunotherapy.
Apply here.


                     

Science & Research

Call for Comment: Cancer Immunotherapy Guidelines for Prostate Cancer

The SITC Cancer Immunotherapy Guidelines Task Force for Prostate Cancer has created guidelines to provide evidence-based consensus recommendations for the use of cancer immunotherapy in the clinical management of prostate carcinoma. Because our membership is comprised of the world’s leading authority on cancer immunotherapy, we are seeking your feedback on this important manuscript before it is published. Share your feedback.

Open to SITC members only. The review period closes on August 7, 2016 at 5:00 pm EST.

New Anti-PD-1 Trial for HIV Patients

The Clinical Trials Immunotherapy Network (CITN), in close collaboration with the National Cancer Institute (NCI) AIDS Malignancy Branch, has opened a trial of anti-PD-1 (pembrolizumab) in patients with HIV and advanced malignancy. In the past, patients with HIV have been systematically excluded from trials of checkpoint inhibitors. The trial is assessing safety, efficacy and the potential role of anti-PD-1 against this chronic viral disease. The trial is open at the NCI and will be opening soon at other CITN sites. If patients don’t have adequate insurance or funds, the therapy at the NCI is free, including transportation to the NCI. Learn more.

Membership

Join SITC or Renew Your Membership Today!

There is still time to enjoy these exciting member benefits! Learn more.

• Save up to $400 on SITC 2016 registration

• Free article submission to JITC ($2,500 value)

• Free access to slide decks from archived live SITC events

• Voting privileges for the upcoming SITC election (Regular and Emeritus members)

• Eligibility for Fellowship and Young Investigator Awards (accepting applications now)

Do You Love Being Part of SITC? Connect-a-Colleague

             • 56 SITC members have already referred over 85
            colleagues for membership

          • Use our online tool to send a personalized invitation to
            your colleagues. All you need is a name and email
            address

Check out our leaderboard.

Publications

JITC – The Resource for Cutting-Edge Science in the Field

Publish in the Journal for ImmunoTherapy of Cancer (JITC), SITC's official open access, peer-reviewed journal. SITC members receive waived article processing charges for papers accepted through 2016.

In Case You Missed It

Read "Cancer immunotherapy trials: Leading a paradigm shift in drug development." SITC leaders review several cancer immunotherapy trial case studies and propose strategies for meeting the challenges encountered during the design and execution of these trials.

Read the other articles in this month’s issue.

ADVERTISEMENT

Society for Immunotherapy of Cancer (SITC)
555 East Wells Street, Suite 1100 | Milwaukee, Wisconsin 53202-3823 USA
Phone: +1 414 271 2456 | Email: info@sitcancer.org

© 2016 Society for Immunotherapy of Cancer

Join us on:

       

If you do not wish to be included in our mailing list, please forward this message to info@sitcancer.org with the word "Remove" in the subject line.

Please add info@sitcancer.org to your safe senders list.